chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Rash, redness axillary, thighs, face, torso, soles of feet, palms of hands, inside of ears, itching ? Allergic reaction, doesn't look like varicella or measles. Denies any hx of anything new. Non toxic, looks happy, no other symptoms besides rash. Went to ER.
Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced PAIN IN EXTREMITY (Sore arm). At the time of the report, PAIN IN EXTREMITY (Sore arm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product information was not provided. Treatment information was not provided.
Acute and then slowly progressive onset of muscle pain and weakness that progressed to right-sided carpal tunnel within two weeks after the injections. The muscle pain and weakness is bilateral and mostly in the shoulders and upper leg area. Progressive and severely debilitating fatigue leading to disability. Elevated CRP above 20 and elevated anti-nuclear antibodies when she was previously healthy and asymptomatic before these injections.
The 0.3 ml pfizer dose was given without the vial the vial being diluted. Undiluted  dose was given
The next day after recieving Gardasil and Menactra vaccines pt began to have fever and vomiting as well as headache. On the second day after vaccination she began to experience right hand tremor and left foot numbness. 03/20/07-records received from facility for DOS 3/6-3/9/07. DC DX: Mild Guillain Barre Syndrome status post intravenous immune globulin. Developed subjective fever and feeling ill as well as vomiting. Started having numbness of left foot shaking of right hand and headache. C/O initial chest pain with cough.Suspected Guillain Barre and treatment included immune globulin.  Neuro consult plan included IVIG. PE:WNL except for not able to dorsiflex or plantar flex at all as well as limitation although some movement of toes with active motion. Did not elicit ankle jerk at the left. Toes were downgoing on Babinski. Gait slightly unsteady
Redness/rash at injection site (8 days post-vaccine). Itching. Roughly 1-1.5" in size to start, then overnight increased another 1-1.5" in length. More itching.
Vial of vaccine improperly reconstituted. Patient's mother notified. Patient re-vaccinated with proper dosing of 0.3ml on 7/10/2021 at 1310. RN observed for 20 minutes post vaccination. No problems.
Left upper arm is red, and hot to touch with a welt at the injection site, temperature has been between 100 and 100.6 (oral). Client is taking Tylenol for fever and discomfort, cool compress to injection site.
30 min, c/o feeling light headed, BP 129/71, 98% RA, HR 66, R 16. Sx resolved.
Patient states that 10 days after vaccination he began to have swelling, numbness, tingling, and coolness in his L foot. He now reports that he has numbness and tingling in both feet and hands. His L foot continues to be the most affected.
no adverse event; dose of VARIVAX was administered after a temperature excursion; This spontaneous report was received from other health professional and refers to a patient of unknown age and gender.  The patient's medical history, concurrent conditions, and concomitant therapies were not reported.  On 07-SEP-2022, the patient was vaccinated with a dose of varicella virus vaccine live (oka/merck) (VARIVAX), lot #W002601, expiration date: 24-JAN-2024 (strength, anatomical location, and route of administration were not provided) as prophylaxis, after experienced a temperature excursion of 5.7 Fahrenheit degree during 30 minutes with a previous temperature excursion of 6 to 14 Fahrenheit degree for 1 hour and 6 minutes. No adverse event was reported.  This is one of two cases reported by the same reporter.; Sender's Comments:  US-009507513-2209USA004009:
Persistent diarrhea after each intacke of food.  Started apporx 1 wk after 1st dose and became increasingly severe after 2nd dose.  Weight loss.  Developed Shingles several months later.  Symptoms eventually resolved by June 2022.
I periodically experience aphthous ulcers in my mouth that respond very consistently (100%) to treatment with topical Triamcinolone Acetonide. Even a single application will significantly reduce the size, duration, and severity of a developing ulcer.  I happened to have two small aphthous ulcers at the time I got the second dose of the Moderna vaccine, and those ulcers were completely nonresponsive to what became very aggressive treatment (topical Triamcinolone Acetonide 4x daily for 2 weeks.)  The size, duration, and severity (pain) of those two ulcers were as if they were completely untreated, despite continuous, aggressive treatment. (Ulcers grew to several millimeters in diameter, took ~2 weeks to subside, caused severe pain that interfered with eating/brushing/talking.)  I did not happen to have any aphthous ulcers at the time of the first dose of the vaccine. I also experienced whole body aches, chills, and fatigue with both doses of the vaccine.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 09Sep2022 at 14:00 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 69 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing); "Ace inhibitors allergy" (unspecified if ongoing). There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Patient received Paxlovid from 09Apr2023 to 13Apr2023 for COVID-19 treatment.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300161873 same reporter/patient, different product/events;
a rash around the vaccine injection site; body fatigue; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). Other Case identifier(s): LRN4711618.  A 37-year-old female patient received BNT162b2 (BNT162B2), in Nov2021 as dose number unknown, single (Batch/Lot number: unknown) at the age of 37 years for COVID-19 immunisation. The patient's relevant medical history included: "Multiple sclerosis" (ongoing); "Pain usually in lower half of body" (ongoing); "Muscle spasms" (ongoing); "Difficulty walking" (ongoing); "Balance Issues" (ongoing); "Allergy to sulfa based drugs" (ongoing); "Use of a cane" (ongoing); "Use of a walker" (ongoing). The patient's concomitant medications were not reported. The following information was reported: VACCINATION SITE RASH (non-serious) with onset Nov2021, outcome "recovered" (Nov2021), described as "a rash around the vaccine injection site"; FATIGUE (non-serious) with onset Nov2021, outcome "recovered" (Nov2021), described as "body fatigue".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
swelling; redness; pain; fever; This case was reported by a pharmacist via call center representative and described the occurrence of swelling in a 63-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 15th August 2020, the patient received the 1st dose of Shingrix. On an unknown date, less than a week after receiving Shingrix, the patient experienced swelling, erythema, injection site pain and fever. On an unknown date, the outcome of the swelling, erythema, injection site pain and fever were recovering/resolving.   It was unknown if the reporter considered the swelling, erythema, injection site pain and fever to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. On 15th August 2020 the patient received Shingrix that patient had experienced swelling, redness, pain and fever.  The patient was wondering about the safety of a second shot given the adverse events of the first one.  The reporter consented to follow up.
Patient describes development of metallic  taste and headache after vaccine administration . No other symptoms reported . No dizziness , sob, difficulty ambulating / standing noted . Patient sent home with ER precautions  and told to follow-up with PCP.
Day 1 sore arm, Day 2 stomach ache and itching, Day 3 itching and arm ache, Day 4 hand ache, Day 6 sore shoulder, Day 7 sore shoulder, 21 days later sore shoulder
I developed tinnitus, could be some correlation with the vaccine for tinnitus; This is a spontaneous report from a contactable consumer (patient).   A patient of an unspecified gender and age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot Number: unknown), via an unspecified route of administration on an unspecified date in Jul2021 as dose 2, single for covid-19 immunization. Patient had no relevant medical history. The patient concomitant medications were not reported. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 1, on an unspecified date for covid-19 immunization. The patient had the Pfizer two shots, the second was in July and as of yesterday the patient developed tinnitus and just came, never had it in the patient life, came out of nowhere and was looking online with a, could be some correlation with the vaccine for tinnitus. The patient just take, the only and did not take any medicine just take one medicine, it was Flomax (Further clarification unknown, hence suspect captured conservatively) the patient spoke to the urologist he said that this should not cause tinnitus. The patient stated, It was two, not immediately, the patient just, two months later, the patient had no idea what cause this.  QR Comment: Reporter type could not be probed as the consumer hung up the call abruptly, hence captured by default as consumer or other non-health professional in tab.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Received vaccine 12/23/20. On 12/31/20 noticed a 3 1/2 inch diameter reddened area to injection site. Area swollen. On 1/5/21 area decreased to light red but still swollen.
Nonstop dizziness 2.5 weeks post 2nd vaccine.  Sever vertigo if standing or bending over.  Vitals perfect and preformed 2x daily.  I am a trained CMA with no underlying health conditions.  This has not only impaired my daily functions, but halted them altogether now.
PATIENT'S DAUGHTER WHO IS AN RN CALLED AND INFORMED US THAT SHE NOTICED THAT HER MOM HAD A RED LEFT SHOULDER (IT WAS WARM TO THE TOUCH) AND THERE WAS SWELLING/WHAT LOOKED TO APPEAR LIKE FLUID BUILD UP TILL THE EPICONDYL (ELBOW).  SHE GAVE HER MOM IBUPROFEN.  PT WAS GIVEN PNEUMOVAX 23 IN THE LEFT ARM.  I ADVISED HER TO CALL PT'S MD  AND TOLD HER TO CONTINUE APPLYING ICE AND GIVING IBUPROFEN.  IF THE CONDITION WORSENS BETWEEN NOW AND TOMORROW TO CALL MD. PT'S DAUGHTER STATED THAT SHE WOULD TAKE HER MOM IN TO SEE THE DOCTOR AND WOULD KEEP AN EYE ON THE ARM.  I TOLD HER THAT A PHARMACIST WILL CONTACT HER IN THE MORNING TO SEE HOW SHE'S DOING AND THAT WE WILL REPORT THIS AS AN ADVERSE EVENT TO THE PNEUMOVAX. PT'S DAUGHTER SAID THAT HER MOM RECEIVED PNEUMONIA VACCINATIONS TWO TIMES BEFORE BUT WAS UNSURE IF IT WAS PREVNAR OR PNEUMOVAX
Chills lasting 4 hours Extreme Fatigue lasting 24 hours All over body aches lasting 30 hours Treated with over the counter acetaminophen which helped relieve symptoms
Received immunizations on 8/14/07. Developed mushy, army green colored stools 8/17/07. Mom noticed blood in stool (mucus strands) on 9/4/07. Stool cxs ordered-never brought sample in. No blood in stool noted again.
pt got sinopharm covid vaccine early 2021 but only got first shot of that series.  came and got booster on 12/29. Were advised to get another dose by physicians... they said they did not get full series.  Called and confirmed with facility specialist.  Official recommendation is if full series of Sinopharm is not completed, to get 1 full dose of either moderna or pfizer.  If full dose is not given, it is to be repeated once. Since we only gave 1/2 dose moderna booster, it was repeated today for a full and final dose
5 hours after receiving HPV pt had low grade fever (99), felt dizzy, pale, had a blotchy red rash on both arms (upper) onto back. No rash elevation, no hives. Pt went to bed, rash was gone by am without further side effects.  During episode heart was also pounding.
Was around someone with COVID. Soon after started sneezing and coughing with a fever. Took home COVID-19 test and was positive. Dr. prescribed Paxlovid was prescribed. Finished full course and tested negative for COVID-19 on 08/02/2022.
Dizziness, chills, abdominal cramping, felt like i was going to throw up, temporary blurry vision, couldn't hear correctly temporarily.
Admitted to COVID unit 9/28 with 2 liters. Oxygen requirements continued to increase. On date of death 70 L/min Heated High-flow.
I started to have a lack of energy on Monday afternoon. On Tuesday I was so exhausted so my husband advised me to take a at home COVID-19 test that came back positive. I called the nurse. I was advised to quarantine for 5 days and wear a mask for the following 5 days. They did not prescribe any medication. I had a fever and I treated the fever with Dayquil.
PATIENT TOOK HER COVID-19 SHOT  AND AFTER SEATING FOR 15 MINUTES; PATIENT WENT ACROSS THE PHARMACY TO SHOP WITH HER  MOM WERE SHE PASSED OUT TO THE FLOOR . THE EMS CAME AND TOOK HER TO THE HOSPITAL FOR FURTHER EXAMINATION.
Expired vaccine used; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 35-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Nov-2021 at 10:00 AM, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Nov-2021 at 10:00 AM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 19-Nov-2021 at 10:00 AM, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported No treatment medication was reported   This case was linked to MOD-2021-391981 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 23-Nov-2021: Additional reporter details, Patient demographics were updated.
Muscle aches, body rash, swelling in fingers, decreased circulation in fingers leading to necrotic gangrene causing middle finger on right hand to be amputated .  Symptoms started end of March and finger was amputated may 26th.
I tested positive with an at home test after  having sore throat, cough, fever, body aches and chills. I had a telehealth visit to discuss my symptoms. At that time a lot of the symptoms has resolved. I declined additional treatment as my symptoms were improving. I took OTC Tylenol and ibuprofen for the first 3 day. I am not all the way there yet as I am still testing positive and still have mild symptoms.
pain, swelling, heat, large red rash not extending to elbow, but circumferential to inner and outer upper arm
Intentionally missed second dose appointment; bad reaction to the first dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Intentionally missed second dose appointment) and ADVERSE EVENT FOLLOWING IMMUNISATION (bad reaction to the first dose) in a 90-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 018B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Intentionally missed second dose appointment) and ADVERSE EVENT FOLLOWING IMMUNISATION (bad reaction to the first dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Intentionally missed second dose appointment) and ADVERSE EVENT FOLLOWING IMMUNISATION (bad reaction to the first dose) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment and concomitant medicines were not reported   This case was linked to MOD21-088635 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 10-May-2021: Additional information received on 10-May-2021 contains no new information.; Sender's Comments:  MOD21-088635:cross linked id
Case symptom onset 7/22/2021 included chills, headache, fatigue, cough, abdominal pain and diarrhea. As of 7/30/2021 case was still symptomatic.
case felt sick for 2 weeks prior to testing positive on 2/1 and then admitted to hospital for 3 days
Abdominal discomfort; Abdominal pain; Lightheaded/Dizzy; Having trouble taking deep breaths/couldn't breath; Sweating; Hyperventilating; Developed blotchy skin; Shaking; Headache; Vomited; A spontaneous report (United States) was received from a health care professional concerning a 50-year-old, female patient who received Moderna's COVID-19 vaccine and experienced abdominal discomfort, abdominal pain, lightheaded/dizzy, having trouble taking deep breaths/couldn't breathe, sweating, hyperventilating, developed blotchy skin, shaking, headache, and vomited.   The patient's medical history included current conditions of mild osteopenia, gastroesophageal reflux disease, anemia, and allergic reaction (anaphylaxis) to metoclopramide. Concomitant products known to have been used by the patient, within two weeks prior to the event, included cefixime, ibuprofen, omeprazole, estradiol, and hydrocodone bitartrate, paracetamol.     On 22 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot number: 011J20A) in their left arm for prophylaxis of COVID-19 infection.   On 22 Dec 2020, the patient told a medical assistant in the waiting area that she felt ill to her stomach and she was having trouble taking deep breaths. The patient was found in a nearby bathroom sitting on the floor. She had vomited, reported she was lightheaded, couldn't breath, was shaking, had abdominal discomfort, and was sweating. It was attempted to move the patient to a wheelchair, but she did not respond well to the transfer. The patient reported the symptoms worsening: headache, abdominal pain, and developed blotch skin, hyperventilating, and was dizzy. A code blue was called and the patient was given a 0.5mg Epinephrine injection. The patient was sent to the emergency room. Treatment for the event included 0.5mg Epinepherine injection, famotidine, ondansetron HCl, prednisone 60mg, and lorazepam 1mg intravenously.   Action taken with mRNA-1273 in response to the events was not provided.  The events abdominal discomfort, abdominal pain, lightheaded/dizzy, having trouble taking deep breaths/couldn't breathe, sweating, hyperventilating, developed blotchy skin, shaking, headache, and vomited were considered not resolved.; Reporter's Comments: This case concerns a 50 year old female patient with medical history of mild osteopenia, gastroesophageal reflux disease, anemia, and allergic reaction (anaphylaxis) to metoclopramide, who experienced events of Abdominal discomfort, Abdominal pain, Dizziness, Dyspnoea, Hyperhidrosis, Hyperventilation, Rash macular, Tremor, Headache, and Vomiting following their first of two planned doses of mRNA-1273 (Lot number: 011J20A). The patient was found ill in the waiting room after leaving clinic prior to completing 15 minute observation time. Very limited information regarding the events has been provided at this time. Based on temporal association between the use of the product and the onset of the events, a causal relationship cannot be excluded.
Vaccine vial opened on (14-may-2021) ,administered to the patient on (19-may-2021); Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine vial opened on (14-may-2021) ,administered to the patient on (19-may-2021)) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine vial opened on (14-may-2021) ,administered to the patient on (19-may-2021)). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine vial opened on (14-may-2021) ,administered to the patient on (19-may-2021)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   no treatment information was reported no concomitant mediation were reported   Reporter did not allow further contact
DEATH; This spontaneous report received from a consumer via a company representative via social media concerned a male of unspecified age, race and ethnic origin. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported, expiry: unknown) dose, 1 total, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the patient died from unknown cause of death. It was reported that "I have a relative that lost both of his parents within 2 days of the jab. They are among the official death counts attributed to the jab." It was unknown if autopsy was performed. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. This report was serious (Death). This case, from the same reporter is linked to 20220112398.; Sender's Comments: V0: 20220112752 -Covid-19 vaccine ad26.cov2.s- Death. This event is considered unassessable. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event.; Reported Cause(s) of Death: UNKNOWN CAUSE OF DEATH
Narrative: COVID infection following COVID vaccine series 01/26, Pfizer, dose #1 02/17, Pfizer, dose #2 09/13, Pfizer, dose #3 1/1 COVID swab, result: detected 12/18 pt cc: headache, cough, shortness of breath exposure: unknown 1/1 pt admit to ED cc: dx COVID19, LOS: 1 day 1/1 CXR impression: acute cardiopulmonary disease. 1/3 clinically resolved
Fatigue, Intermittent stabbing pains moving everywhere around my body  continuously; skin sensative to touch with burning feeling, swollen glands under armpits, neck..  Lasting now over a week. Some lessening with GabaPenton prescription after telehealth consult. His thinking it was  neuropathic pain.